European Companies Search Engine

Tips & Tricks
Our help pages Using the Quick Search and Power Search Overview explain how to use our search engine.

UCB Biopharma B.V., Anderlecht, Belgium

Watch

If you put a company on your watch list, we'll notify you on your email address when there are new publications regarding this company.

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Dossier

The dossier is a printable PDF file, summarizing information and publications for this company. The creation of dossiers is included in your subscription. After the creation of the dossier is completed, it will be sent to your email address .

Add to dossier (if available):

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Name

UCB Biopharma B.V.

Identification

Kbo
Crossroads Bank for Enterprises (KBO) 0543.573.053
Chp
Companies House OE030470
Lei
21380029O1RSZIAVOR95
EUID
BEKBOBCE.0543.573.053

Address

Researchdreef 60, 1070 Anderlecht, Belgium

Corporate purpose

72.10
Research and experimental development on natural sciences and engineering
21.20
Manufacture of pharmaceutical preparations
72.11
Research and experimental development on biotechnology

Financials

History

Persons

Marketing & Tech

Network

Loading network

DATA SERVICES

Unlock the full potential of processed company data with our API or Quarterly Exports.

Publications

Year 2025 in Epobase
6 European patent filings: Chromatography …
1 Nov 2025 via Amgen Inc.
EU funding: Unifying Framework for Patient-centred Clinical-study Endpoints derived from Digital Health Technologies
2 Oct 2025
Belgian Official Gazette
17 Jul 2025 in United Kingdom also 31/07/2024
Filings
10 Jul 2025
Wordmark: “CIM-Pal“
3 Jul 2025 as UCB Biopharma Sàrl
Annual report for the year ending 31/12/2024 · Balance sheet for 31/12/2024 · Earnings statement for 31/12/2024 · No longer Member of the board: Dhavalkumar Patel · Board member (4) · SH (5 companies)
3 Jun 2025
Persons
19 May 2025 via UCB Pharma N.V. also 06/08/2024, 13/05/2024, 17/05/2023, 23/05/2022
Shareholder: UCB Pharma N.V
12 May 2025
Auditor (1)
13 Apr 2025
Wordmark: “NEUROTAINMENT“
18 Mar 2025
Manager (1)
11 Jan 2025
Wordmark: “EPI-MANAGER“
29 Dec 2024
Capital: €3.59B · Company statute
Year 2024 in Hor also 18/12/2024
5 EU fundings (€0.00): Comprehensive methodological and operational approach to clinical trials in rare and ultra-rare diseases …
22 Nov 2024
Word figurative mark: “K“
Year 2024 in Epobase
13 European patent filings: A Substituted Tetrahydroisoquinoline Derivative AS a D1 Positive Allosteric Modulator …
Year 2024 in Epobase
15 European patent filings: Dihydro-Cyclopenta-Isoquinoline Derivatives …
31 Jul 2024
Registered Design: Wallets
31 Jul 2024
Registered Design: Wallets
16 Jul 2024 as UCB Biopharma Sàrl
Annual report for the year ending 31/12/2023 · Balance sheet for 31/12/2023 · Earnings statement for 31/12/2023 · Member of the board (4) · Shareholder (5 companies)
10 Jul 2024
Director: Alistair Henry · No longer Director: Dhavalkumar Patel · Auditor (1)
5 May 2024
Wordmark: “EPI-INTERACT“
Year 2023 in Epobase
31 European patent filings: Treatment of Fibromyalgia …
Year 2023 in Epobase
32 European patent filings: Fused Imidazole Derivatives AS IL-17 Modulators …
4 Aug 2023
Persons
21 Jul 2023 as UCB Biopharma Sàrl
Annual report for the year ending 31/12/2022 · Balance sheet for 31/12/2022 · Earnings statement for 31/12/2022 · No longer Member of the board: William Silbey · Board member (3) · SH (4 companies)
17 Jul 2023 in United Kingdom
Reg­is­tra­tion: 17/07/2023
14 Jul 2023
Director: D. Waynick Johnson · No longer Director: William Silbey
Year 2022 in Epobase
20 European patent filings: Method for Detecting and/or Quantifying Crosslinks Formed by Transglutaminases …
Year 2022 in Epobase
27 European patent filings: Antimalarial Hexahydropyrimidine Derivatives …
26 Sept 2022 in Sat
State Aid (€9,401,879): Walloon Decree on Innovation
26 Jul 2022
Auditor (1) · Company statute
18 Jul 2022 as UCB Biopharma Sàrl
Annual report for the year ending 31/12/2021 · Balance sheet for 31/12/2021 · Earnings statement for 31/12/2021 · Member of the board (4) · Shareholder (5 companies)
Year 2022 in Euipotm
4 trademark filings (3 wordmarks, 1 word figurative mark): LUMIIMG, PSOCADEMY, RYSTIGGO …
Year 2022 in Euipotm
4 trademark filings (3 wordmarks, 1 word figurative mark): LUMIIMG, PSOCADEMY, RYSTIGGO …
Year 2022 in Euipods
6 registered designs
Year 2022 in Euipods
6 registered designs
4 Feb 2022
Wordmark: “NEUROXCHANGE“
Year 2021 in Epobase
38 European patent filings: Amorphous Solid Dispersions …
Year 2021 in Epobase
80 European patent filings: A Substituted Tetrahydroisoquinoline Derivative AS a D1 Positive Allosteric Modulator …
1 Nov 2021 in Hor
EU funding: European platform for neurodegenerative disorders
1 Oct 2021 in Hor
EU funding: Shortening the path to rare disease diagnosis by using newborn genetic screening and digital technologies
12 Jul 2021
BRINGING ALL ACTIONS TOGETHER IN ONE HAND - MERGE
1 Jul 2021
Persons
1 Jul 2021 in Hor
EU funding: Health Initiatives in Psoriasis and PsOriatic arthritis ConsoRTium European States
20 May 2021
Manager (1)
11 May 2021
Wordmark: “MYBE“
10 Mar 2021
Word figurative mark: “osteo Xchange“
9 Feb 2021
Registered Design: Connector housings
9 Feb 2021
Registered Design: Connector housings
Year 2020 in Epobase
48 European patent filings: Dihydro-Cyclopenta-Isoquinoline Sulfonamides Derivatives …
Year 2020 in Epobase
67 European patent filings: Dihydro-Cyclopenta-Isoquinoline Sulfonamides Derivatives …
21 Dec 2020
Wordmark: “ORIGINERIKUM“
4 Dec 2020 in Hor
EU funding: Central Repository for Digital Pathology
6 Nov 2020
Wordmark: “BONEBOT“
1 Nov 2020 in Hor
EU funding: Gravitate–Health: Empowering and Equipping Europeans with health information for Active Personal Health Management and Adherence to Treatment
28 Oct 2020
Director (2)
14 Oct 2020
Wordmark: “MYMAB“
4 Aug 2020
No longer Director: Detlef Thielgen · Director (1) · Auditor (1)
29 Jul 2020
Wordmark: “MYBODY“
1 Jan 2020 in Hor
EU funding: PharmaLedger
Year 2019 in Epobase
45 European patent filings: Phenyl-Urea and Phenyl-Carbamate Derivatives AS Inhibitors of Protein Aggregation …
Year 2019 in Epobase
46 European patent filings: Phenyl-Urea and Phenyl-Carbamate Derivatives AS Inhibitors of Protein Aggregation …
Year 2019 in Euipotm
9 trademark filings (5 wordmarks, 4 word figurative marks): CIMPLYME, CamillaCares, Daisy and me, My Jasmine, VeroniCares …
Year 2019 in Euipotm
9 trademark filings (5 wordmarks, 4 word figurative marks): CIMPLYME, CamillaCares, Daisy and me, My Jasmine, VeroniCares …
4 Dec 2019 as UCB Biopharma SPRL
Director (4) · Capital: €563M · Legal form
Year 2019 in Hor also 01/11/2019
8 EU fundings (€256,320): Identifying Digital Endpoints to Assess FAtigue, Sleep and acTivities in daily living in Neurodegenerative disorders and Immune-mediated inflammatory diseases …
10 Oct 2019 as UCB Biopharma SPRL
Managing Director: William Silbey
3 May 2019 as UCB Biopharma SPRL
Auditor (1) · Capital: €1.39B
24 Jan 2019 as UCB Biopharma SPRL
No longer Managing Director: Anna Richo · Managing Director (1)
18 Dec 2018 as UCB Biopharma SPRL
Persons · Capital: €1.35B
Year 2018 in Epobase
10 European patent filings: Anti-Alpha Synuclein Antibodies …
Year 2018 in Epobase
10 European patent filings: Anti-Alpha Synuclein Antibodies …
Year 2018 in Hor also 01/12/2018
8 EU fundings (€0.00): European Screening Centre; Unique Library for Attractive Biology …
26 Sept 2018
Wordmark: “BYBE“
9 Jan 2018
Wordmark: “ABRIVIANZ“
27 Dec 2017 as UCB Biopharma SPRL
Managing Director: N.N., Dhavalkumar Patel · No longer Managing Director: Fabrice Enderlin, Ismail Kola
Year 2017 in Epobase
12 European patent filings: Medical USE of Interferon-Lambda for the Treatment of Fibrosis …
Year 2017 in Epobase
8 European patent filings: Gremlin-1 Crystal Structure and Inhibitory Antibody …
Year 2017 in Euipotm
7 trademark filings (3 wordmarks, 1 figurative mark, 3 word figurative marks): ABRIVILEA, BREVALENCE, ELIPRIO …
Year 2017 in Euipotm
8 trademark filings (4 wordmarks, 1 figurative mark, 3 word figurative marks): ABRIVILEA, BREVALENCE, ELIPRIO, NUBRIVEO …
Year 2017 in Dpmap
10 patent filings: Tetrahydroisochinolin Derivate …
14 Sept 2017 as UCB Biopharma SPRL
Managing Director: Detlef Thielgen · Auditor (1)
1 Sept 2017 in Hor
EU funding: Rheuma Tolerance for Cure
28 Aug 2017 in Hor
EU funding: European Quality In Preclinical Data
1 Feb 2017 in Hor
EU funding: Big Data for Better Outcomes, Policy Innovation and Healthcare System Transformation - Sofia ref.: 116055
27 Jan 2017 as UCB Biopharma SPRL
Managing Director: Fabrice Enderlin · No longer Managing Director: Mark McDade
Year 2016 in Dpmap
20 patent filings: Kondensierte Trizyklische Imidazopyrazine ALS Modulatoren der TNF-Activität …
Year 2016 in Epobase
22 European patent filings: Multi-Specific Antibody Molecules Having Specificity for TNF-Alpha, IL-17A and IL-17F …
Year 2016 in Epobase
25 European patent filings: Multi-Specific Antibody Molecules Having Specificity for TNF-Alpha, IL-17A and IL-17F …
12 Dec 2016 in Sat
State Aid: Walloon Decree on Innovation
12 Dec 2016 in Sat
State Aid (€675,421): Walloon Decree on Innovation
Year 2016 in Euipotm
5 wordmarks: AVA, BIQAN, SID, UCBCares, VERSE
Year 2016 in Euipotm
5 wordmarks: AVA, BIQAN, SID, UCBCares, VERSE
18 Jul 2016 as UCB Biopharma SPRL
CROSS-BORDER MERGER
16 Jun 2016 as UCB Biopharma SPRL
Annual report (only deposited)
3 Jun 2016 as UCB Biopharma SPRL
Capital: €1.99B
1 Apr 2016 in Hor
EU funding: Remote Assessment of Disease and Relapse in Central Nervous System Disorders
31 Mar 2016 as UCB Biopharma SPRL
Persons · Capital: €1.99B
24 Mar 2016 as UCB Biopharma SPRL
Managing Director (2)
21 Jan 2016 as UCB Biopharma SPRL
Managing Director: Fabrice Enderlin, Ismail Kola, Anna Sessan Richo
Year 2015 in Dpmap
65 patent filings: Multispezifische Antikörperkonstrukte …
Year 2015 in Epobase
6 European patent filings: Protein Manufacture …
Year 2015 in Epobase
8 European patent filings: Method of Protein Manufacture …
Year 2015 in Euipotm
6 trademark filings (2 wordmarks, 4 word figurative marks): CIM-Pal, TRYBE …
11 Sept 2015
Wordmark: “TRYBE“
27 Aug 2015 via Instn
EU funding (€250,560): ISOTOPIC LABELING FOR DRUG INNOVATION
20 Aug 2015
Word figurative mark: “CimpleCare“
11 Aug 2015 via Glaxosmithkline Research & Development Ltd.
EU funding: Targeted small-molecule Stabilisation of Protein-Protein Interactions
10 Jul 2015 as UCB Biopharma SPRL
Annual report (only deposited)
7 Jul 2015 as UCB Biopharma SPRL
Managing Director: Detlef Thielgen · Manager (1) · No longer Auditor (1)
1 Jul 2015 in Hor
EU funding: Accelerated Development of Appropriate Patient Therapies: a Sustainable, Multi-stakeholder Approach from Research to Treatment-outcomes - Sofia ref.: 115890
29 Jun 2015
Word figurative mark: “CimpleTrack“
12 Nov 2014
Patent: Antibodies Specific to FCRN
26 Aug 2014
Patent: Antibodies Against CSF-1R
14 Jul 2014 as UCB Biopharma SPRL
Auditor (1) · Capital: €1.87B · Company statute
Year 2014 in Dpmap
10 patent filings: Einzellinker-Fabfv-Antikörper und Verfahren zur Herstellung Davon …
20 Jun 2014 as UCB Biopharma SPRL
Persons
15 May 2014 as UCB Biopharma SPRL
Auditor (1) · Capital: €1.46B · Company statute
18 Mar 2014 as UCB Biopharma SPRL
Managing Director: Fabrice Enderlin
24 Dec 2013 as UCB Biopharma SPRL
Reg­is­tra­tion: 24/12/2013 · Managing Director: Fabrice Enderlin, Mark McDade, Detlef Thielgen · Manager (1) · Capital: €18,600.00
There are no publications matching your search.

Mentions

10 Jan 2025 in Ler
Direct parent: UCB N.V
10 Jan 2025 in Ler
Ultimate parent: UCB N.V
30 Dec 2022 in Kbo
Acquisition: Handl Therapeutics B.V
12 Jan 2017 in Ler
Direct parent: UCB Pharma N.V
There are no publications matching your search.

The data on this page is generated by a fully automated algorithm. It may have errors, and is provided on an "as is" basis with no guarantees of completeness, accuracy, usefulness or timeliness.

Creative Commons License The visualizations for "UCB Biopharma B.V., Anderlecht, Belgium" are provided by North Data and may be reused under the terms of the Creative Commons CC-BY license.

Printing is only available to North Data premium service subscribers.